Baclofen (Gablofen, Lioresal Intrathecal, Fleqsuvy, Lyvispah, Ozobax, Ozobax DS)
Clinical policy governing medical necessity criteria, initial and continued therapy requirements, dosing limits, contraindications, and product availability for intrathecal and oral baclofen formulations across Centene lines of business (Commercial, HIM, Medicaid). Includes coding implications and prior review history.
Added Ozobax DS formulation to policy.
Removed requirement for compounded baclofen oral solution or baclofen crushed/split tablets and added requirement for generic baclofen oral solution.
Gablofen/Lioresal requirement for oral baclofen revised to 'Documentation supports inability to use' language.
Added newly FDA approved Lyvispah oral granules and Fleqsuvy oral suspension to policy.
Updated product availability, contraindications and boxed warnings per PI.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.